Takeda Acquires Rights to Cx601, Possible Stem Cell Therapy for Perianal Fistulas in Crohn’s Patients

Takeda Acquires Rights to Cx601, Possible Stem Cell Therapy for Perianal Fistulas in Crohn’s Patients
Takeda Pharmaceuticals has entered an exclusive licensing agreement with TiGenix to develop and commercialize Cx601 as a treatment for complex perianal fistulas in patients with Crohn’s disease. The agreement applies to Europe, specifically, where an application for the drug’s approval has already been filed. Cx601 is a suspension of allogeneic adipose-derived stem cells (eASC) applied as an

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *